Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

Blood

Volumn 100, Issue 2, 2002, Pages 391-396

  Shibolet, Oren ^a,b,c   Ilan, Yaron ^a,b,c   Gillis, Shmuel ^a,b,c   Hubert, Ayala ^a,b,c   Shouval, Daniel ^a,b,c   Safadi, Rifaat ^a,b,c  

^a Division of Medicine   (Israel)

^b Department of Hematology ^*  (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CRYOGLOBULINEMIA; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LYMPHOMA; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; SEROCONVERSION; VIRUS CARRIER; VIRUS REACTIVATION;

EID: 0037100514     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.2.391     Document Type: Article

References (41)

1. Hepatitis B virus infection
2. The epidemiology of hepatitis B virus among family members in the Middle East
3. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management
4. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case controlled study
5. Reactivation of chronic HBV infection after bone marrow transplantation
6. Reactivation of chronic hepatitis B infection by cancer chemotherapy
7. Occurrence and management of hepatitis B virus reactivation following kidney transplantation
8. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors
9. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: Precore/core mutations may play an important role
10. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers
11. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma
12. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study
13. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients
14. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier
15. Severe hepatitis related to chemotherapy in hepatitis B carriers with hematologic malignancies
16. A preliminary trial of lamivudine for chronic hepatitis B infection
17. A one year trial of lamivudine for chronic hepatitis B
18. Lamivudine as initial treatment for chronic hepatitis B in the United States
19. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
20. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
21. Recovery from lifethreatening corticosteroid-unresponsive chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy
22. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: Case report and review of the literature
23. Hepatitis B reactivation after lamivudine
24. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation
25. Reactivation of hepatitis B in a long-term anti-HBspositive patient with AIDS following lamivudine withdrawal
26. Immunosuppression and reactivation of hepatitis B in the lamivudine era: Opportunities for prevention and exploitation?
27. Case report: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy
28. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
29. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma
30. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity
31. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice
32. Hepatitis B virus contains a glucocorticoidresponsive element
33. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: Clinical course and possible treatment with ganciclovir
34. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation
35. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
36. Lamivudine treatment can overcome ctytotoxic T cell hyporesponsiveness in chronic hepatitis B: New perspective for immune therapy
37. Lamivudine resistance in immunocompetent chronic hepatitis B: Incidence and patterns
38. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
39. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
40. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: A report on three cases and review of the literature
41. Persistent hepatitis B infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"